Aug 30, 2019
Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Aug 30, 2019
Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering
Aug 09, 2019
Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
Jun 19, 2019
Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design
May 09, 2019
Sophiris Bio Reports First Quarter 2019 Financial Results
Apr 02, 2019
Sophiris Bio to Present at Two Upcoming Investor Conferences
Mar 13, 2019
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
Dec 17, 2018
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
Sep 25, 2018
Sophiris Bio to Present at the Cantor Global Healthcare Conference
Sep 14, 2018
Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
Aug 29, 2018
Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial
Aug 14, 2018
Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
Jun 25, 2018
Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer
May 14, 2018
Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights
Mar 21, 2018
Sophiris Bio Reports Fourth Quarter and Full Year 2017 Financial Results and Key Corporate Highlights
Mar 15, 2018
Sophiris Bio to Present at 17th Annual Needham Healthcare Conference
Dec 27, 2017
Sophiris Bio to Participate in the 10th Annual Biotech Showcase Conference
Dec 11, 2017
Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer
Nov 27, 2017
Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference
Nov 09, 2017
Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights